NCT01995188 is a Phase 1 clinical trial of Bevacizumab in Non-Squamous Non-Small Cell Lung Cancer, sponsored by Genentech, Inc..

Who is sponsoring NCT01995188?

NCT01995188 is sponsored by Genentech, Inc..

What drugs are being tested in NCT01995188?

Interventions in NCT01995188: Bevacizumab, Carboplatin, DNIB0600A.

What condition does NCT01995188 study?

NCT01995188 studies Non-Squamous Non-Small Cell Lung Cancer.

Is NCT01995188 still recruiting?

NCT01995188 is currently completed. Last updated 4 October 2017.

Last reviewed 2017-10-04 · How we verify

NCT01995188

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

Completed Phase 1 Last updated 4 October 2017

What this trial tests

Phase 1 trial testing Bevacizumab in Non-Squamous Non-Small Cell Lung Cancer in 41 participants. Completed in 9 November 2016.

Timeline

16 December 2013

Primary endpoint
9 November 2016

9 November 2016

Quick facts

Lead sponsor	Genentech, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	16 December 2013
Primary completion	9 November 2016
Estimated completion	9 November 2016
Sites	4 locations across United States

Drugs / interventions tested

Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
DNIB0600A — full drug profile →

Conditions studied

Non-Squamous Non-Small Cell Lung Cancer — all drugs for Non-Squamous Non-Small Cell Lung Cancer →

Sponsor

Genentech, Inc. — full company profile →

Who can join

18 and older, any sex, with Non-Squamous Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This open-label, multicenter, phase 1b study will evaluate the safety and pharmacokinetics of DNIB0600A in participants with platinum-sensitive ovarian cancer (PSOC) or Non-Squamous Non-small Cell Lung Cancer (NSCLC). The maximum tolerated dose of intravenously infused DNIB0600A in combination with carboplatin will be determined in escalating dose cohorts. The combination of DNIB0600A and carboplatin will then be evaluated with and without bevacizumab \[Avastin\] in three dose expansion cohorts.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Exploration of the antibody-drug conjugate clinical landscape.
Maecker H, Jonnalagadda V, Bhakta S, Jammalamadaka V, et al · · 2023 · cited 90× · PMID 37639687 · DOI 10.1080/19420862.2023.2229101
Antibody-drug conjugates in lung cancer: dawn of a new era?
Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, et al · · 2023 · cited 89× · PMID 36631624 · DOI 10.1038/s41698-022-00338-9
Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates.
Newman DJ, Cragg GM. · · 2017 · cited 43× · PMID 28353637 · DOI 10.3390/md15040099
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
Vacchelli E, Pol J, Bloy N, Eggermont A, et al · · 2015 · cited 32× · PMID 25949870 · DOI 10.4161/2162402x.2014.985940
The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
Liu X, Deng J, Zhang R, Xing J, et al · · 2023 · cited 15× · PMID 38162667 · DOI 10.3389/fimmu.2023.1335252
Therapeutic targets and new directions for antibodies developed for ovarian cancer.
Bax HJ, Josephs DH, Pellizzari G, Spicer JF, et al · · 2016 · cited 14× · PMID 27494775 · DOI 10.1080/19420862.2016.1219005
Lung cancer organoid-based drug evaluation models and new drug development application trends.
Lee E, Lee SY, Seong YJ, Ku B, et al · · 2024 · cited 4× · PMID 39830742 · DOI 10.21037/tlcr-24-603
Therapeutic landscape of ovarian cancer: recent advances and emerging therapies.
Wang L, Zhang Q, Wang X, Dong Z, et al · · 2025 · cited 2× · PMID 40797342 · DOI 10.1186/s40364-025-00818-7

Verify or expand the search:

Other trials of Bevacizumab

Trials testing the same drug.

NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07500298 — Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable · Phase 1 · not yet recruiting
NCT07271355 — Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colore · Phase 3 · not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting

Other recruiting trials for Non-Squamous Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06417008 — A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer · Phase 2, PHASE3 · recruiting

Other Genentech, Inc. trials

Trials by the same sponsor.

NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
NCT07214662 — A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01995188 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genentech, Inc.
Last refreshed: 4 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01995188.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing